Lipocine director granted 1,764 stock options

Lipocine Inc. director Jene Jill M. received a grant of stock options covering 1,764 shares of common stock at an exercise price of $2.19 per share.

Rhea-AI Filing Summary

Lipocine Inc. director Jene Jill M. received a grant of stock options covering 1,764 shares of common stock at an exercise price of $2.19 per share. These options vest 100% one year from the grant date and expire on June 3, 2036. Following this grant, the director holds a total of 8,938 derivative securities directly.

Insights

Equity compensation analyst

Routine stock option grant to Lipocine director as equity compensation.

Lipocine Inc. granted director Jene Jill M. 1,764 stock options with a $2.19 exercise price, vesting fully one year after the grant and expiring on June 3, 2036. The filing classifies this as a grant or award acquisition rather than a market purchase.

After this grant, the director directly holds 8,938 derivative securities. This type of equity award is a standard governance practice to align director incentives with long-term shareholder value, rather than a signal-driven open-market trade.

Insider Trade Summary

Grant/Award: 1,764 shares

Grant/Award 1 txn

Insider Jene Jill M.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	1,764	$2.19	$4K

Holdings After Transaction: Stock Option (Right to Buy) — 8,938 contracts (Direct)

Footnotes (1)

1. F1. 100% vesting one year from date of grant.

Key Figures

Options granted: 1,764 options Exercise price: $2.19 per share Total derivative holdings: 8,938 securities +2 more

5 metrics

Options granted 1,764 options Stock Option (Right to Buy) grant on June 3, 2026

Exercise price $2.19 per share Conversion or exercise price of granted options

Total derivative holdings 8,938 securities Total derivative securities following transaction

Vesting period 1 year 100% vesting one year from grant date

Option expiration June 3, 2036 Expiration date of granted options

Key Terms

Stock Option (Right to Buy), Grant, award, or other acquisition, derivative securities, vesting

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

derivative securities financial

"total_shares_following_transaction shows 8,938 derivative securities"

Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.

vesting financial

"Footnote states 100% vesting one year from date of grant"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Lipocine (LPCN) director Jene Jill M. receive in this Form 4 filing?

The director received a grant of 1,764 stock options to buy Lipocine common shares at $2.19 per share. This award is classified as a grant or other acquisition, not an open-market share purchase or sale.

What is the vesting schedule for the new Lipocine (LPCN) stock options?

The options vest 100% one year from the date of grant. This means the director must remain in service for one year before any of the 1,764 options become exercisable for common shares.

What is the exercise price and expiration date of the Lipocine (LPCN) options granted?

Each option has an exercise price of $2.19 per share and an expiration date of June 3, 2036. After vesting, the director can buy shares at this fixed price any time before expiration.

How many derivative securities does the Lipocine (LPCN) director hold after this grant?

Following the grant, the director is reported to hold 8,938 derivative securities in total. This figure reflects the aggregate number of derivative positions directly owned after adding the 1,764 newly granted options.

Does this Lipocine (LPCN) Form 4 show any stock being bought or sold in the market?

No, the transaction is classified as a grant or award acquisition of options, not a market trade. There are no open-market purchases or sales; it is equity compensation granted by the company to the director.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/04/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jene Jill M.

(Last) (First) (Middle)

675 ARAPEEN DRIVE

SUITE 202

(Street)

SALT LAKE CITY UTAH 84108

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Lipocine Inc. [ LPCN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.19	06/03/2026		A		1,764		06/03/2027(1)	06/03/2036	Common Stock	1,764	$2.19	8,938	D

Explanation of Responses:

1. 100% vesting one year from date of grant.

	/s/ Jill M. Jene	06/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)